10x Genomics, Inc. — Director's Dealing 2021

Nov 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-11-12

Reporting Person: CRUTCHFIELD BRADFORD (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-12	Class A Common Stock	M	17000	$1.16	Acquired	60336	Direct
2021-11-12	Class A Common Stock	S	1030	$163.1013	Disposed	59306	Direct
2021-11-12	Class A Common Stock	S	4122	$164.1760	Disposed	55184	Direct
2021-11-12	Class A Common Stock	S	6872	$164.8665	Disposed	48312	Direct
2021-11-12	Class A Common Stock	S	4776	$165.8932	Disposed	43536	Direct
2021-11-12	Class A Common Stock	S	100	$167.27	Disposed	43436	Direct
2021-11-12	Class A Common Stock	S	100	$168.34	Disposed	43336	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-12	Stock Option (right to buy)	$1.16	M	17000	Disposed	2027-02-03	Class A Common Stock (17000)	Direct

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $162.49 to $163.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $163.50 to $164.495. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $164.50 to $165.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $165.51 to $166.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This option, originally for 800,000 shares, of which 357,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.